Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taipei Exchange - Delayed Quote TWD

Bioptik Technology Incorporation (4161.TWO)

Compare
34.50
-0.30
(-0.86%)
At close: April 2 at 1:30:34 PM GMT+8
Loading Chart for 4161.TWO
  • Previous Close 34.80
  • Open 34.75
  • Bid 34.25 x --
  • Ask 34.55 x --
  • Day's Range 34.05 - 34.80
  • 52 Week Range 27.50 - 38.50
  • Volume 49,451
  • Avg. Volume 85,761
  • Market Cap (intraday) 1.826B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 19.17
  • EPS (TTM) 1.80
  • Earnings Date --
  • Forward Dividend & Yield 0.70 (2.03%)
  • Ex-Dividend Date Jul 16, 2024
  • 1y Target Est --

Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.

www.bioptik.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4161.TWO

View More

Performance Overview: 4161.TWO

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4161.TWO
12.20%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

4161.TWO
4.07%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

4161.TWO
47.66%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

4161.TWO
33.15%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 4161.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4161.TWO

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    1.83B

  • Enterprise Value

    1.86B

  • Trailing P/E

    19.17

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.07

  • Price/Book (mrq)

    2.03

  • Enterprise Value/Revenue

    2.14

  • Enterprise Value/EBITDA

    11.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.81%

  • Return on Assets (ttm)

    3.76%

  • Return on Equity (ttm)

    10.68%

  • Revenue (ttm)

    865.33M

  • Net Income Avi to Common (ttm)

    93.57M

  • Diluted EPS (ttm)

    1.80

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    422.29M

  • Total Debt/Equity (mrq)

    41.59%

  • Levered Free Cash Flow (ttm)

    115.68M

Research Analysis: 4161.TWO

View More

Company Insights: 4161.TWO

Research Reports: 4161.TWO

View More

People Also Watch